How should Baxter International balance increasing the shelf life of its intravenous solutions against potential increases in production costs?

Introduction

Balancing the shelf life extension of Baxter International's intravenous solutions against potential production cost increases is a critical trade-off that impacts multiple aspects of the business. This scenario involves weighing the benefits of longer-lasting products against the financial implications of modifying production processes. I'll analyze this trade-off by examining the product, stakeholders, metrics, and potential experiments to inform a strategic decision.

Step 1

Clarifying Questions (3 minutes)

• Based on the current market dynamics, I'm thinking shelf life might be a key differentiator. Could you provide more context on how our shelf life compares to competitors'?

Why it matters: Helps assess competitive advantage and urgency of the initiative Expected answer: Our shelf life is average or slightly below competitors Impact on approach: Would prioritize shelf life extension if we're lagging behind

• Considering our business model, I assume longer shelf life could impact inventory management and sales cycles. How does our current shelf life align with typical hospital ordering patterns?

Why it matters: Determines potential value to customers and impact on sales strategy Expected answer: Current shelf life sometimes causes issues with hospital inventory Impact on approach: Would focus on aligning new shelf life with hospital needs

• Looking at user impact, I'm curious about the clinical implications. Are there any safety or efficacy concerns related to extending the shelf life of our IV solutions?

Why it matters: Ensures we prioritize patient safety and regulatory compliance Expected answer: No significant concerns, but rigorous testing would be required Impact on approach: Would incorporate extensive quality assurance in the plan

• From a technical perspective, I'm wondering about the scalability of potential shelf life extension methods. What production technologies are we currently using, and how flexible are they?

Why it matters: Determines feasibility and cost implications of implementation Expected answer: Current tech is moderately flexible, but major changes would be costly Impact on approach: Would explore incremental improvements vs. complete overhaul

• Regarding resources, I'm thinking this could be a significant undertaking. What's our current R&D capacity and budget allocation for product improvements?

Why it matters: Helps assess our ability to execute on shelf life extension initiatives Expected answer: Moderate R&D capacity with some budget flexibility Impact on approach: Would tailor the scope of the project to available resources